Ultragenyx Pharmaceutical RARE Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Collaboration And Royalty | $93M-36.2% | $145.79M+30.2% | $111.94M-7.0% | $120.41M+16.9% | $103M-11.1% | |
| Non Cash Royalty | $20M-46.8% | $37.58M+50.9% | $24.91M-17.8% | $30.32M+59.6% | $19M-43.4% | |
| Royalty | $47M-55.5% | $105.6M+62.6% | $64.94M-24.2% | $85.68M+78.5% | $48M-48.5% | |
| Royalty Percentage On Net Sales by Geography | ||||||
| European Union And Switzerland And Turkey | 10%— | —— | —— | —— | 10%— | |
| Royalty Revenue For Sales In North American Territiory | 30%— | —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Ultragenyx Pharmaceutical break its business down?
- Ultragenyx Pharmaceutical (RARE) reports revenue by product across 3 parts — Collaboration And Royalty, Non Cash Royalty and Royalty. Each is extracted from the segment footnotes and tracked over time.
- Where does Ultragenyx Pharmaceutical's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Ultragenyx Pharmaceutical's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
